- Home
- Publications
- Publication Search
- Publication Details
Title
MEDI 4736 (durvalumab) in non-small cell lung cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 17, Issue 10, Pages 1317-1323
Publisher
Informa UK Limited
Online
2017-07-14
DOI
10.1080/14712598.2017.1351939
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
- (2016) S.J. Antonia et al. ANNALS OF ONCOLOGY
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) S. Novello et al. ANNALS OF ONCOLOGY
- A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
- (2016) David Planchard et al. Clinical Lung Cancer
- 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
- (2016) T. Mok et al. Journal of Thoracic Oncology
- 129TiP: SAKK 16/14 – anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial
- (2016) S.I. Rothschild et al. Journal of Thoracic Oncology
- 191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
- (2016) S. Peters et al. Journal of Thoracic Oncology
- 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC
- (2016) D.L. Gibbons et al. Journal of Thoracic Oncology
- 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
- (2016) M.-J. Ahn et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells
- (2016) Xin Liu et al. Scientific Reports
- PD-L1 Blockade for Cancer Treatment: MEDI4736
- (2015) Ramy Ibrahim et al. SEMINARS IN ONCOLOGY
- Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
- (2015) R. Stewart et al. Cancer Immunology Research
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2009) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now